All AbMole products are for research use only, cannot be used for human consumption.
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain with IC50 of 1.0 nM and Ki value of 0.02 nM. Deucravacitinib (BMS-986165) inhibited IL-23, IL-12, and Type I interferon-driven cellular signaling and transcriptional responses (IC50 range 2-14 nM).
Deucravacitinib (BMS-986165) treatment in NZB/W lupus-prone mice rapidly (24 hours) reduced the elevated expression of Type I interferon-dependent genes and dose-dependently protected from nephritis and other disease endpoints with chronic dosing, with efficacy correlating with inhibition of Type I interferon-dependent gene expression. Deucravacitinib (BMS-986165) was also highly efficacious in the anti-CD40-induced colitis model in SCID mice, providing protection against both weight loss (wasting) and histologically evident colitis, and was as effective as an anti-p40 antibody.
PLoS Pathog. 2024 Apr 15;20(4):e1012136.
African swine fever virus pB318L, a trans-geranylgeranyl-diphosphate synthase, negatively regulates cGAS-STING and IFNAR-JAK-STAT signaling pathways
Deucravacitinib (BMS-986165) purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | CD3+ T-cells, CD161+ CD3+ T-cells, TF-1 cells, mononuclear cells, platelets |
| Preparation method | Deucravacitinib (BMS-986165) is evaluated in both binding and human cellular assays to determine selectivity within the JAK family and across the kinome. Mean values are determined from at least three separate experiments unless otherwise noted. Measuring STAT5 phosphorylation in CD3+ T-cells as end point. Measuring STAT3 phosphorylation in CD161+ CD3+ T-cells. Measuring STAT5A phosphorylation in TF-1 cells (n = 2). Measuring STAT6 phosphorylation in mononuclear cells (n = 2). Measuring STAT5 phosphorylation in platelets. Measuring STAT3 phosphorylation in CD3+ T-cells. |
| Concentrations | 0-10 μM |
| Incubation time | - |
| Animal Experiment | |
|---|---|
| Animal models | 6−8 weeks old C57BL/6 female mice |
| Formulation | - |
| Dosages | 7.5 mg/kg, 15 mg/kg, and 30 mg/kg |
| Administration | oral gavage |
| Molecular Weight | 425.46 |
| Formula | C20H19D3N8O3 |
| CAS Number | 1609392-27-9 |
| Solubility (25°C) | DMSO ≥ 30 mg/mL |
| Storage | -20°C |
| Related JAK Products |
|---|
| iJak-381
iJak-381 is a JAK1/2 inhibitor with anti-inflammatory activity. |
| Ritlecitinib (malonate)
Ritlecitinib (PF-06651600) malonate is an orally active and selective JAK3 inhibitor with an IC50 of 33.1 nM. |
| Deuruxolitinib
Deuruxolitinib is a deuterated Ruxolitinib (INCB18424), which modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research of hair loss disorders. |
| A-005
A-005 is a potentially first-in-class, brain-penetrating TYK2 allosteric inhibitor for studies related to neuroinflammatory and neurodegenerative diseases. |
| Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
